Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

2.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]

3.

High content screen for identifying small-molecule LC3B-localization modulators in a renal cancer cell line.

Kolla L, Heo DS, Rosenberg DP, Barlow SA, Maximova AA, Cassio EE, Buchser WJ.

Sci Data. 2018 Jun 26;5:180116. doi: 10.1038/sdata.2018.116.

4.

Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.

Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, Kim CW, Jeon YK.

Oncoimmunology. 2018 Mar 13;7(7):e1442164. doi: 10.1080/2162402X.2018.1442164. eCollection 2018.

5.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

PMID:
29682899
6.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2018 Apr 5. doi: 10.4143/crt.2017.491. [Epub ahead of print]

7.

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.

Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, Kim BS, Kang JH, Lee KH, Kim SW, Ryoo HM, Kim JS, Lee KH, Kwon JH, Choi JH, Shin SW, Hahn S, Heo DS.

Cancer Res Treat. 2018 Mar 12. doi: 10.4143/crt.2018.019. [Epub ahead of print]

8.

CD21-independent Epstein-Barr virus entry into NK cells.

Lee JH, Choi J, Ahn YO, Kim TM, Heo DS.

Cell Immunol. 2018 May;327:21-25. doi: 10.1016/j.cellimm.2018.01.011. Epub 2018 Jan 17.

PMID:
29499908
9.

The impact of caregiver's role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver's disclosure of terminal disease status.

Yoo SH, Yun YH, Kim KN, Lee JL, Park J, Choi YS, Lim YK, Kim S, Jeong HS, Kang JH, Oh HS, Park JC, Kim SY, Song HS, Lee KS, Heo DS, Hong YS.

Qual Life Res. 2018 Jun;27(6):1571-1581. doi: 10.1007/s11136-018-1814-7. Epub 2018 Feb 24.

PMID:
29478132
10.

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.

Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, Keam B, Kim TM, Kim JS, Choi IS, Heo DS.

Korean J Intern Med. 2018 Feb 23. doi: 10.3904/kjim.2017.174. [Epub ahead of print]

11.

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS.

Yonsei Med J. 2018 Mar;59(2):202-210. doi: 10.3349/ymj.2018.59.2.202.

12.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

13.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

14.

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.

Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4.

PMID:
29204702
15.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS.

Korean J Intern Med. 2017 Nov 20. doi: 10.3904/kjim.2017.036. [Epub ahead of print]

16.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.

17.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

18.

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):720-728. doi: 10.4143/crt.2017.169. Epub 2017 Jul 14.

19.

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives.

Koh SJ, Kim S, Kim J, Keam B, Heo DS, Lee KH, Kim BS, Kim JH, Chang HJ, Baek SK.

Cancer Res Treat. 2018 Apr;50(2):614-623. doi: 10.4143/crt.2016.446. Epub 2017 Jul 3.

20.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.

21.

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS.

J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.

PMID:
28498782
22.

Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience.

Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, Paik JH, Lee JM, Lee HY, Lee JS, Heo DS, Lee JO.

Leuk Lymphoma. 2017 Nov;58(11):2624-2632. doi: 10.1080/10428194.2017.1312376. Epub 2017 May 9.

PMID:
28482727
23.

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.

Park S, Kim JY, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Heo DS.

Korean J Intern Med. 2017 May;32(3):514-522. doi: 10.3904/kjim.2015.299. Epub 2017 Apr 14.

24.

Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.

Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA.

Cancer Res Treat. 2017 Oct;49(4):1033-1043. doi: 10.4143/crt.2016.413. Epub 2017 Apr 7.

25.

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS.

Am J Pathol. 2017 May;187(5):980-986. doi: 10.1016/j.ajpath.2017.01.004. Epub 2017 Mar 9.

PMID:
28284718
26.

Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.

Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Kim NJ, Heo DS, Park WB, Oh MD.

Cancer. 2017 Mar 1;123(5):841-848. doi: 10.1002/cncr.30468. Epub 2016 Dec 20.

27.

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.

Shin J, Keam B, Kim M, Park YS, Kim TM, Kim DW, Kim YW, Heo DS.

J Thorac Oncol. 2017 Mar;12(3):520-528. doi: 10.1016/j.jtho.2016.11.2216. Epub 2016 Nov 17.

28.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Park S, Park S, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Kim YW, Heo DS.

Korean J Intern Med. 2016 Nov;31(6):1140-1149. Epub 2016 Mar 28.

29.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.

Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K.

Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.

PMID:
27803005
30.

Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.

Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK.

Virchows Arch. 2016 Nov;469(5):581-590. Epub 2016 Sep 5.

PMID:
27595782
31.

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.

Kim R, Keam B, Kwon D, Ock CY, Kim M, Kim TM, Kim HJ, Jeon YK, Park IK, Kang CH, Kim DW, Kim YT, Heo DS.

World J Gastroenterol. 2016 Oct 7;22(37):8389-8397.

32.

The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea.

Baek SK, Chang HJ, Byun JM, Han JJ, Heo DS.

Cancer Res Treat. 2017 Apr;49(2):502-508. doi: 10.4143/crt.2016.073. Epub 2016 Sep 1.

33.

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.

Kim M, Keam B, Kim TM, Kim HG, Kim JS, Lee SS, Shin SH, Kim MK, Park KU, Kim DW, Yun HJ, Lee JS, Heo DS.

Cancer Res Treat. 2017 Apr;49(2):416-422. doi: 10.4143/crt.2016.121. Epub 2016 Jul 28.

34.

The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.

Kim SK, Kim TM, Lee ST, Lee SH, Heo DS, Kim IH, Kim DG, Jung HW, Choi SH, Lee SH, Park CK.

J Clin Neurosci. 2016 Dec;34:145-150. doi: 10.1016/j.jocn.2016.06.014. Epub 2016 Jul 27.

PMID:
27475318
35.
36.

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.

Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS.

Cancer Res Treat. 2017 Jan;49(1):129-140. doi: 10.4143/crt.2015.466. Epub 2016 May 18.

37.

Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications.

Paik JH, Choe JY, Kim H, Lee JO, Kang HJ, Shin HY, Lee DS, Heo DS, Kim CW, Cho KH, Kim TM, Jeon YK.

Leuk Lymphoma. 2017 Jan;58(1):53-63. Epub 2016 May 9.

PMID:
27157296
38.

WITHDRAWN:Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.

Korean J Intern Med. 2016 Apr 21. [Epub ahead of print]

39.

Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer.

Park S, Park S, Lee SH, Suh B, Ock CY, Keam B, Kim TM, Kim DW, Kim YW, Heo DS.

Cancer Biomark. 2016;16(3):425-33. doi: 10.3233/CBM-160581.

PMID:
27062699
40.

Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

Sim SH, Beom SH, Ahn YO, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.

Thorac Cancer. 2016 Mar;7(2):161-6. doi: 10.1111/1759-7714.12304. Epub 2015 Aug 28.

41.

Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.

Ock CY, Keam B, Kim TM, Han DH, Won TB, Lee SH, Hah JH, Kwon TK, Kim DW, Kim DY, Rhee CS, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2016 May;31(3):570-8. doi: 10.3904/kjim.2015.020. Epub 2016 Mar 15.

42.

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.

Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI.

BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.

43.

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).

Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, Lee DH, Kim DW, Jung M, Choi JH, Shim HS, Choi JR, Kim JH.

Lung Cancer. 2016 Mar;93:1-8. doi: 10.1016/j.lungcan.2015.12.005. Epub 2015 Dec 29.

PMID:
26898607
44.

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2016 Mar 29;7(13):15901-14. doi: 10.18632/oncotarget.7431.

45.

Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study.

Kim R, Ock CY, Keam B, Kim TM, Kim JH, Paeng JC, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.

BMC Cancer. 2016 Feb 17;16:116. doi: 10.1186/s12885-016-2147-y.

46.

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.

Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Clin Cancer Res. 2016 May 1;22(9):2261-70. doi: 10.1158/1078-0432.CCR-15-2834. Epub 2016 Jan 27.

47.

ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.

Kang MK, Oh D, Cho KH, Moon SH, Wu HG, Heo DS, Ahn YC, Park K, Park HJ, Park JS, Keum KC, Cha J, Kim JW, Kim YS, Kang JH, Oh YT, Kim JY, Kim SH, Kim JH, Lee CG.

Cancer Res Treat. 2016 Jan;48(1):425. doi: 10.4143/crt.2014.141.2.

48.

MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.

Park S, Koh J, Kim DW, Kim M, Keam B, Kim TM, Jeon YK, Chung DH, Heo DS.

Lung Cancer. 2015 Dec;90(3):381-7. doi: 10.1016/j.lungcan.2015.10.022. Epub 2015 Oct 27.

PMID:
26791796
49.

Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors.

Yang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS.

Cancer Immunol Res. 2016 Mar;4(3):215-24. doi: 10.1158/2326-6066.CIR-15-0118. Epub 2016 Jan 19.

50.

An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Nam SJ, Kim S, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.

Leuk Lymphoma. 2016 Aug;57(8):1956-60. doi: 10.3109/10428194.2015.1117610. Epub 2016 Jan 4. No abstract available.

PMID:
26727587

Supplemental Content

Support Center